PAREXEL EXPERT TO LEAD TRACK ON GLOBAL CLINICAL OUTSOURCING AT PARTNERSHIPS IN CLINICAL TRIALS EUROPE CONFERENCE
Boston, MA, November 8, 2010—Thought leaders from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address best practices in strategic partnering and requirements for successful global clinical development during the 9th Annual Partnerships in Clinical Trials Europe Conference. PAREXEL is a sponsor of the conference, which will be held November 16-19, 2010 in Vienna, Austria.
On Thursday, November 18, Niki Harrop, Corporate Vice President, Project Management, Clinical Research Services, PAREXEL, will chair the track, “International Landscape for Clinical Outsourcing—Getting a Global Footprint for Your Trials”. The track will feature presentations on topics including conducting trials in the Middle East and Asia/Pacific region, as well as other global outsourcing trends.
Experts from PAREXEL will be available at Stand #237 in the exhibit hall to discuss capabilities to support successful global clinical development, ranging from early phase to late phase development and regulatory and market access consulting for product globalization. PAREXEL experts will also address how the Company supports partners in improving development effectiveness through best-practice strategic partnership models that increase operating efficiency.
Attendees can visit experts from Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL, at Stand #311 to learn how its eClinical Suite provides advanced integration and interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. Perceptive’s eClinical Suite supports real-time data interchange and enables diverse applications to work synergistically.
For more information about PAREXEL visit www.PAREXEL.com. For more information about Perceptive Informatics visit: www.perceptive.com. Information about Partnerships in Clinical Trials Europe can be found at http://www.ct-partnerships.com/.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2010 as filed with the SEC on August 27, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.